title: Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.
abstract: PURPOSE The optimal treatment for early-stage, lymphocyte-predominant Hodgkin's lymphoma (LPHL) is not well defined. Treatment has become less aggressive over time in an attempt to reduce iatrogenic complications, such as cardiac mortality and second cancers, but long-term efficacy is unclear. We present the long-term outcome of patients treated at a single institution. PATIENTS AND METHODS The study population includes 113 patients with stage I or II LPHL treated between 1970 and 2005. Pathologic diagnosis for all patients was confirmed using standard criteria. Ninety-three patients received radiation therapy (RT) alone, 13 received RT with chemotherapy, and seven received chemotherapy alone. Among patients treated with RT, 25 received limited-field, 35 received regional-field, and 46 received extended-field RT. Results Median follow-up was 136 months. Ten-year progression-free survival (PFS) rates were 85% (stage I) and 61% (stage II); overall survival (OS) rates were 94% and 97% for stages I and II, respectively. PFS and OS did not differ among patients who received limited-field, regional-field, or extended-field RT. In contrast, six of seven patients who received chemotherapy alone without RT developed early disease progression and required salvage treatment. Multivariable analysis adjusting for extent of RT, clinical stage, sex, and use of chemotherapy confirmed that the extent of RT was not significantly associated with PFS (P = .67) or OS (P = .99). The addition of chemotherapy to RT did not improve PFS or OS compared with RT alone. CONCLUSION RT alone leads to sustained disease control and high long-term survival rates in patients with early-stage LPHL. This study supports the use of limited-field RT alone to treat this disease.
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA.
authors.forename: Ronald C
authors.initials: RC
authors.lastname: Chen
authors.forename: Michael S
authors.initials: MS
authors.lastname: Chin
authors.forename: Andrea K
authors.initials: AK
authors.lastname: Ng
authors.forename: Yang
authors.initials: Y
authors.lastname: Feng
authors.forename: Donna
authors.initials: D
authors.lastname: Neuberg
authors.forename: Barbara
authors.initials: B
authors.lastname: Silver
authors.forename: Geraldine S
authors.initials: GS
authors.lastname: Pinkus
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Stevenson
authors.forename: Peter M
authors.initials: PM
authors.lastname: Mauch
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D006801:Humans; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017211:Treatment Failure